Results 11 to 20 of about 8,213 (210)

Practice of Monitoring Cisplatin-Induced Ototoxicity by Audiology, ENT, and Oncology Specialists: A Survey-Based Study in a Single Italian Medical Center

Audiology Research, 2023
Ototoxic drugs can result in hearing loss and tinnitus. Early detection of the ototoxic process can help minimize or prevent these consequences. The American Speech–Language–Hearing Association has provided guidelines for monitoring ototoxicity, whereas ...
Valeria Gambacorta, Eva Orzan, Mario Faralli, Mario Gullà, Ruggero Lapenna, Irene Baietta, Verena De Angelis, Giampietro Ricci   +7 more
doaj   +3 more sources

A Retrospective Evaluation of Ototoxicity Monitoring in a Cohort of Pediatric Patients With Solid Tumors, Treated in the Dutch National Cancer Center [PDF]

Cancer Reports
Introduction Ototoxicity is an adverse effect of childhood cancer treatment with a negative impact on speech‐language development and quality of life.
Franciscus A. Diepstraten, Odette M. M. Bertram, Hiske W. Helleman, Ralf A. Boerboom, Martine vanGrotel, József Zsíros, Godelieve A. M. Tytgat, Harm vanTinteren, Robert J. Stokroos, Geert O. Janssens, Alex E. Hoetink, Marry M. van denHeuvel‐Eibrink, Annelot J. M. Meijer   +12 more
doaj   +2 more sources

Navigating the Genetic Risk of Chemotherapy-Induced Hearing Loss in the Stria Vascularis. [PDF]

Clin Pharmacol Ther
Cisplatin is a chemotherapy drug that causes permanent hearing loss by damaging a critical tissue lining the inner ear, called the stria vascularis (SV). Currently, the molecular mechanisms of SV damage are largely unknown and the incidence of ototoxicity in patients cannot be reliably predicted.
Lazetic T, Miao DNR, Drögemöller BI, Dabdoub A, Abitbol JM.   +4 more
europepmc   +2 more sources

Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). [PDF]

J Rehabil Res Dev, 2014
Prevention and rehabilitation of hearing loss and tinnitus, the two most commonly awarded service-connected disabilities, are high priority initiatives in the Department of Veterans Affairs (VA). At least 4,000 Veterans, most with significant hearing loss, will receive cisplatin this year, with more than half sustaining permanent hearing shift and ...
Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M.   +4 more
europepmc   +3 more sources

ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring. [PDF]

J Am Acad Audiol, 2013
Background:Nonbehavioral methods for identifying cisplatin ototoxicity are important for testing patients with cancer who become too tired or sick to provide a reliable response. The auditory brainstem response (ABR) is a nonbehavioral test that is sensitive to ototoxicity but can be time consuming to implement over a range of frequencies and/or ...
Dille MF, Ellingson RM, McMillan GP, Konrad-Martin D.   +3 more
europepmc   +4 more sources

Community-Based Ototoxicity Monitoring for Drug-Resistant Tuberculosis in South Africa: An Evaluation Study. [PDF]

Int J Environ Res Public Health, 2021
Stevenson LJ, Biagio-de Jager L, Graham MA, Swanepoel W.   +3 more
europepmc   +2 more sources

Evoked otoacoustic emissions — an approach for monitoring cisplatin induced ototoxicity in children

International Journal of Pediatric Otorhinolaryngology, 2001
Cisplatin chemotherapy is associated with an increased risk of ototoxic changes. The incidence of hearing loss after the 1st cisplatin-infusion session is only scarcely mentioned in the international literature. With increasing survival rates, prevention and/or early detection of ototoxicity are important for providing management options.
Stavroulaki, P, Apostolopoulos, N, Segas, J, Tsakanikos, M, Adamopoulos, G   +4 more
openaire   +5 more sources

Effects of neoadjuvant immunotherapy on hearing in patients with head and neck squamous cell carcinoma [PDF]

Scientific Reports
Immune checkpoint blockade (ICB) is a commonly used treatment modality for cancer with a growing list of oncologic indications. Ototoxicity is a potential immune-related adverse event of ICB treatment, but the risk of hearing loss after ICB remains ...
Bryce Hambach, Anhelina Bilokon, John Lee, L. Noelle Allemang, Jennifer Chisholm, Chris K. Zalewski, Julie Christensen, Carmen C. Brewer, James L. Gulley, Clint T. Allen, Lisa L. Cunningham, Katharine A. Fernandez   +11 more
doaj   +2 more sources

Monitoring neonates for ototoxicity [PDF]

International Journal of Audiology, 2017
Neonates admitted to the neonatal intensive care unit (NICU) are at greater risk of permanent hearing loss compared to infants in well mother and baby units. Several factors have been associated with this increased prevalence of hearing loss, including congenital infections (e.g.
Angela C. Garinis, Alison Kemph, Anne Marie Tharpe, Joern-Hendrik Weitkamp, Cynthia McEvoy, Peter S. Steyger   +5 more
openaire   +2 more sources

Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. [PDF]

, 2020
BACKGROUND: Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia.
Abass, KM, Agossadou, D, Ampadu, EO, Asiedu, KB, Chauty, A, Egondi, TW, Frimpong, M, Ganlonon, L, Gateau, T, Grosset, J, Lehman, L, Macdonald, JM, Marion, E, Ochieng Otieno, M, Ohene, S-A, Omollo, R, Paintsil, A, Phillips, RO, Robert, J, Saizonou, R, Sarfo, FS, Sarpong, G, Sarpong, NF, Saunderson, P, Stienstra, Y, study team, Thompson, W, Tiendrebeogo, A, Treadwell, T, van der Werf, TS, Wansbrough-Jones, M, Wilson, T   +31 more
core   +3 more sources